Literature DB >> 20371618

CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice.

Tomomi Kiyota1, Satoshi Okuyama, Russell J Swan, Michael T Jacobsen, Howard E Gendelman, Tsuneya Ikezu.   

Abstract

Cytokines play an emerging role as neurotransmitters, neuromodulators, and neurohormones in the brain. This paradigm shift in cytokine function offers a new framework to understand their roles in ameliorating neurodegenerative disorders, such as Alzheimer's disease (AD). Molecular adjuvant therapy of AD animal models with glatiramer acetate induces anti-inflammatory responses and therapeutic effects. Although these effects are potentially mediated through anti-inflammatory cytokine signaling, the exact molecular identities and pathways are poorly understood. Here, we show that virus-mediated expression of the mouse interleukin (IL)-4 gene in beta-amyloid precursor protein + presenilin-1 (APP+PS1) bigenic mice attenuates AD pathogenesis. Introduction of an adeno-associated viral (AAV) vector encoding IL-4 into the hippocampus resulted in sustained expression of IL-4, reduced astro/microgliosis, amyloid-beta peptide (Abeta) oligomerization and deposition, and enhanced neurogenesis. Moreover, increased levels of IL-4 improved spatial learning, promoted phosphorylation of N-methyl-D-aspartate receptor subunit 2B at Tyr 1472, and enhanced its cell surface retention both in vivo and in vitro. Our data suggest that neuronal anti-inflammatory cytokine signaling may be a potential alternative target for non-Abeta-mediated treatment of AD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20371618      PMCID: PMC2909296          DOI: 10.1096/fj.10-155317

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  61 in total

1.  Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice.

Authors:  Masaru Yamamoto; Tomomi Kiyota; Masahide Horiba; James L Buescher; Shannon M Walsh; Howard E Gendelman; Tsuneya Ikezu
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

2.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

3.  Downregulation of IL-4-induced signalling in hippocampus contributes to deficits in LTP in the aged rat.

Authors:  F O Maher; Yvonne Nolan; Marina A Lynch
Journal:  Neurobiol Aging       Date:  2005-05       Impact factor: 4.673

4.  Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes.

Authors:  L Holcomb; M N Gordon; E McGowan; X Yu; S Benkovic; P Jantzen; K Wright; I Saad; R Mueller; D Morgan; S Sanders; C Zehr; K O'Campo; J Hardy; C M Prada; C Eckman; S Younkin; K Hsiao; K Duff
Journal:  Nat Med       Date:  1998-01       Impact factor: 53.440

5.  Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1.

Authors:  Oleg Butovsky; Maya Koronyo-Hamaoui; Gilad Kunis; Eran Ophir; Gennady Landa; Hagit Cohen; Michal Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-24       Impact factor: 11.205

6.  Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease.

Authors:  Dan Frenkel; Ruth Maron; David S Burt; Howard L Weiner
Journal:  J Clin Invest       Date:  2005-08-11       Impact factor: 14.808

7.  Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.

Authors:  K Hsiao; P Chapman; S Nilsen; C Eckman; Y Harigaya; S Younkin; F Yang; G Cole
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

8.  Reduced pathology and improved behavioral performance in Alzheimer's disease mice vaccinated with HSV amplicons expressing amyloid-beta and interleukin-4.

Authors:  Maria E Frazer; Jennifer E Hughes; Michael A Mastrangelo; Jennifer L Tibbens; Howard J Federoff; William J Bowers
Journal:  Mol Ther       Date:  2008-03-11       Impact factor: 11.454

9.  Interleukin-10 attenuates production of HSV-induced inflammatory mediators by human microglia.

Authors:  Cristina P Marques; Shuxian Hu; Wen Sheng; Maxim C-J Cheeran; Diana Cox; James R Lokensgard
Journal:  Glia       Date:  2004-09       Impact factor: 7.452

10.  Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain.

Authors:  Ronald L Klein; Mary E Hamby; Yan Gong; Aaron C Hirko; Samuel Wang; Jeffrey A Hughes; Michael A King; Edwin M Meyer
Journal:  Exp Neurol       Date:  2002-07       Impact factor: 5.330

View more
  86 in total

1.  FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders.

Authors:  Tomomi Kiyota; Kaitlin L Ingraham; Michael T Jacobsen; Huangui Xiong; Tsuneya Ikezu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-31       Impact factor: 11.205

2.  The anti-inflammatory glycoprotein, CD200, restores neurogenesis and enhances amyloid phagocytosis in a mouse model of Alzheimer's disease.

Authors:  Megan M Varnum; Tomomi Kiyota; Kaitlin L Ingraham; Seiko Ikezu; Tsuneya Ikezu
Journal:  Neurobiol Aging       Date:  2015-08-01       Impact factor: 4.673

Review 3.  Modulation of learning and memory by cytokines: signaling mechanisms and long term consequences.

Authors:  Elissa J Donzis; Natalie C Tronson
Journal:  Neurobiol Learn Mem       Date:  2014-08-21       Impact factor: 2.877

Review 4.  G-protein-coupled receptors in adult neurogenesis.

Authors:  Van A Doze; Dianne M Perez
Journal:  Pharmacol Rev       Date:  2012-05-18       Impact factor: 25.468

Review 5.  Microglial phenotype and adaptation.

Authors:  B J L Eggen; D Raj; U-K Hanisch; H W G M Boddeke
Journal:  J Neuroimmune Pharmacol       Date:  2013-07-25       Impact factor: 4.147

Review 6.  Gene therapy for misfolding protein diseases of the central nervous system.

Authors:  Waldy San Sebastian; Lluis Samaranch; Adrian P Kells; John Forsayeth; Krystof S Bankiewicz
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

7.  The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal model.

Authors:  Xiqian Lan; Tomomi Kiyota; Richa Hanamsagar; Yunlong Huang; Scott Andrews; Hui Peng; Jialin C Zheng; Susan Swindells; George A Carlson; Tsuneya Ikezu
Journal:  J Neuroimmune Pharmacol       Date:  2011-08-09       Impact factor: 4.147

Review 8.  Anesthetic modulation of neuroinflammation in Alzheimer's disease.

Authors:  Junxia X Tang; Maryellen F Eckenhoff; Roderic G Eckenhoff
Journal:  Curr Opin Anaesthesiol       Date:  2011-08       Impact factor: 2.706

9.  Spinal Cord Injury Impairs Neurogenesis and Induces Glial Reactivity in the Hippocampus.

Authors:  Ignacio Jure; Luciana Pietranera; Alejandro F De Nicola; Florencia Labombarda
Journal:  Neurochem Res       Date:  2017-03-13       Impact factor: 3.996

Review 10.  Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight.

Authors:  Yang Shi; David M Holtzman
Journal:  Nat Rev Immunol       Date:  2018-12       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.